AU Patent

AU2020334943A1 — Heterocyclic THR-β receptor agonist compound and preparation method and use therefor

Assigned to Hepagene Therapeutics HK Ltd · Expires 2022-03-10 · 4y expired

What this patent protects

A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality.

USPTO Abstract

A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020334943A1
Jurisdiction
AU
Classification
—
Expires
2022-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Hepagene Therapeutics HK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.